The present post hoc analysis of the Spanish subset of patients in the ASSESS study further confirms the utility of ctDNA analysis in plasma for the evaluation of EGFR mutation status when tumor tissue is unavailable or exhausted. This evidence concerns the gene EGFR and neoplasm.